BR Biopharma, Inc. (NASDAQ:BRBI) Short Interest Update

BR Biopharma, Inc. (NASDAQ:BRBI) saw a significant drop in short interest during the month of April. As of April 30th, there was short interest totaling 942 shares, a drop of 96.4% from the April 15th total of 26,338 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 3,916 shares, the days-to-cover ratio is presently 0.2 days.

BR Biopharma Stock Performance

Shares of BRBI stock traded down $0.30 during mid-day trading on Monday, hitting $14.15. 2,222 shares of the stock were exchanged, compared to its average volume of 4,138. The firm’s fifty day moving average price is $14.84. BR Biopharma has a 12-month low of $12.15 and a 12-month high of $67.01.

BR Biopharma (NASDAQ:BRBI) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.09 earnings per share (EPS) for the quarter. The firm had revenue of $25.95 million for the quarter.

BR Biopharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Tuesday, May 19th will be issued a dividend of $0.147 per share. The ex-dividend date of this dividend is Tuesday, May 19th. This represents a $0.59 dividend on an annualized basis and a dividend yield of 4.2%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings started coverage on BR Biopharma in a report on Friday, February 13th. They set a “sell (e-)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC purchased a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma comprises approximately 3.2% of Acuitas Investments LLC’s holdings, making the stock its 7th biggest position.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.